London, UK
27-29 November, 2017
Download Agenda

Why Attend

The Annual European Microbiome Congress has become a trusted learning and networking platform for leading academics, practicing clinicians, pharmaceutical and nutrition companies, biotech entrepreneurs and investors, government and regulatory bodies and industry leaders who require insight into the latest microbiome research, clinical trials and multi-disciplinary collaborations.

Join us for 2.5 days of intense networking, unpublished research and translational case studies.

In addition to the open networking available, our ‘MEETING MOJO’ platform allows you to create a bespoke meeting schedule, promoting productive collaboration; and if you are looking to highlight your recent work to the wider microbiome community, the dedicated poster session is a great way to get your research noticed and further involve yourself with the congress!

Our 2017 agenda is now available to view here.

Ratio of Academics - Industry
Microbiome Niches Covered
Leading Top Speakers
Hours of Dedicated Networking

View Video from European Microbiome Congress 2016

European Microbiome Congress, 2016

The Speakers


Esther Jiménez

Project Manager

Jean de Gunzburg


Sacha Mann

Biosys UK

Lihi Segal

Day Two

Muriel Derrien

Gut Microbiota Program Leader
Danone Nutricia Research

Prof. Dr. Michael Schloter

Head of the Research Unit for Comparative Microbiome Analyses
Helmholtz Zentrum München

Professor Curtis Huttenhower

Associate Professor of Computational Biology and Bioinformatics
Harvard School of Public Health

Curtis Huttenhower is an Associate Professor of Computational Biology and Bioinformatics, Harvard University. His lab focuses on understanding the function of microbial communities, particularly that of the human microbiome in health and disease.

This entails a combination of computational methods development for wrangling large data collections, as well as biological analyses and laboratory experiments to link the microbiome in human populations to specific microbiological mechanisms.


Amrita Ahluwalia

Prof of Vascular Pharmacology
Queen Mary University of London

Andrew Morgan

DuPont Fellow & Chief Scientist
Dupont Nutrition & Health

Arpita Maiti

Senior Director, External R&D Innovation, Inflammation & Immunology and Microbiome
University of Oxford

Marie Drago


Dr. Larry Weiss

Chief Medical Officer

Larry Weiss MD is the Chief Medical Officer at AOBiome. He has an extensive background in natural products chemistry, microbiology, clinical medicine, and pharmaceutical development and commercialization. Dr. Weiss is board certified in Anesthesiology, has an MD from Stanford University Medical School, and a BS from Cornell University in Biochemistry. He has a number of patents and is published in the areas of chemistry, electrophysiology, and microbiology. Dr. Weiss is the founder of CleanWell Company.


Dr David Cook

Chief Scientific Officer

David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. (“Seres”). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr.


Céline Druart

Assistant Researcher, Metabolism and Nutrition Research Group
Louvain Drug Research Institute

Dr James Kinross

Senior Lecturer in Colorectal Surgery
Imperial College London

Dr. James Kinross is a consultant colorectal surgeon, at St. Mary’s Hospital London. His clinical interests are in minimally invasive and laparoscopic surgery for the treatment of colorectal cancer. He also has an interest in surgical nutrition and modulation of the gut microbiota by pro and prebiotics for improved operative outcomes. He was trained in Northwest London, and he was an NIHR Clinical Lecturer in Surgery and an Ethicon Laparoscopic Fellow in Colorectal Surgery.


Shannon Doyle


Johan van Hylckama Vlieg

Vice President Microbiome & Human Health Innovation
Chr. Hansen A/S

Johan E.T. van Hylckama Vlieg is currently Senior Director Microbiome at Chr. Hansen AS, one of the largest microbe producing companies in the world. He is responsible for microbiome innovation program and heading the microbiome research and pilot facility. He has 20 years of experience and leadership in gut microbiology, probiotics and food biotechnology in industry and academia. He is (co)author of more than 70 peer-reviewed publications and inventor of 13 patents or patent applications.


Professor Julian Marchesi

Professor of Human Microbiome Research
Cardiff University

Julian Marchesi graduated from Cardiff University with a PhD in biochemistry (1992) and became interested in the role bacteria play in ecosystem function. During his post-doctoral years he developed an interest in the contribution of uncultured microbes to the maintenance and function of ecosystems i.e. molecular microbial ecology.


David Kyle

Evolve Bioscystems

Dr Kyle has been CEO of Evolve BioSystems Inc. since 2014. The company is focused on changing the standard of care of babies based on new understandings of the interrelationship between the baby, the baby’s microbiome, and mother’s milk. He previously acted as an advisor to bio-tech start-ups through the DJK Consulting, a firm he founded in 2010 after founding two biotech businesses of his own; Martek Biosciences and Advanced BioNutrition Corp.


Professor David Berry

Associate Professor, Microbial Ecology
University of Vienna

David Berry is Associate Professor at the University of Vienna.

His research interests include:

  • Function of the intestinal microbiota in health and disease
  • Numerical approaches to study microbial communities
  • Development of molecular and isotope-labeling methods for studying uncultivated microorganisms in their natural environment

He has 28 publications in peer-reviewed journals, including in leading multidisciplinary and discipline-specific journals such as: Proc Natl Acad Sci USA, Cancer Res, FEMS Microbiol Rev, and ISME J.


Dr Trevor Lawley

Group Leader Host- Microbiota Interactions Laboratory
Wellcome Trust Sanger Institute

Trevor obtained his PhD from the University of Alberta, Canada, where he studied the mechanisms that pathogenic bacteria use to disseminate antibiotic resistance genes. In 2010, Trevor was appointed as a Career Development Fellow in the Sanger Institute Faculty and was promoted to Group Leader in 2014. He receives funding from the Medical Research Council. Trevor’s research investigates the mechanisms that underlie how micro-organisms on mucosal surfaces (gut, nasopharnyx, uro-gential tract) interact with their host during periods of health and disease.


Professor Tim Spector

Professor of Genetic Epidemiology
Kings College London

Tim Spector is a Professor of Genetic Epidemiology and Director of the TwinsUK Registry at Kings College, London. He trained originally in rheumatology and epidemiology. In 1992 he moved into genetic epidemiology and founded the UK Twins Registry, of 13,000 twins, which is the richest collection of genotypic and phenotypic information worldwide. He is past President of the International Society of Twin Studies, directs the European Twin Registry Consortium (Discotwin) and collaborates with over 120 centres worldwide.


Professor Max Nieuwdorp

Professor of internal medicine and diabetes
AMC Amsterdam

Dr Nieuwdorp is currently working as an internist-endocrinologist and Head of the department of Experimental Vascular Medicine at the Academic Medical Centre (AMC) within the University of Amsterdam. He has initiated a translational research group focused on dissecting the causal role of (small) intestinal bacterial strains to reverse insulin resistance, adipose tissue inflammation and cardiovascular disease. Dr Niuewdorp is also Visiting Professor at the University of Gothenburg.


Joseph Sliman

Chief Medical Officer (CMO)
Synthetic Biologics

From January 13, 2014 until January 17, 2017, Dr. Sliman served as the Company’s Senior Vice President-Clinical & Regulatory Affairs. Dr. Sliman has more than 18 years of experience in clinical and public health research, including 10 years directing clinical projects and product development, in therapeutic areas such as infectious diseases and vaccines. From September 2012 until January 2014, Dr.


Professor Jeroen Raes

Group Leader Bioinformatics and (eco-)Systems Biology
VIB, KULeuven

Jeroen Raes is group leader of the Bioinformatics and (eco-)Systems Biology (BSB) research group at VIB in Brussels. He has an extensive track record in meta-omics and microbiome research.


Dr. Gregor Reid

Professor of Microbiology and Immunology and Surgery
Western University

Dr. Gregor Reid is a professor of Microbiology and Immunology and Surgery at Western University, and the Endowed Chair in Human Microbiome and Probiotics at the Lawson Health Research Institute. Dr. Reid’s research interests include: Microbiome and probiotics, Women’s health, Environmental influences on health, and Genitourinary systems. Having been a pioneer of probiotic research and the study of microbes in the urogenital tract of women, his research has expanded to studies of the gut, breast, heart and use of probiotics to detoxify environmental pollutants. Dr.


Denise Kelly

Investment Advisor

Denise joined Seventure in September 2015 as an investment Advisor to the Life Sciences Team for microbiome field.

Her focus is in Human Microbiome Research and her time is dedicated to coverage of scientific and academic community on behalf of Seventure, and to prospect new investment opportunities in the specific field of microbiome.


Ian MacLeod

Senior Associate
Carpmaels & Ransford

Ian is a UK and European Patent Attorney and his practice covers a wide range of biotechnological subject-matter, with particular focus on live biotherapeutics, biomarker diagnostics, vaccines, antibody therapeutics, and antisense nucleotides.



Aletta Kraneveld

Professor of Pharmacology
Utrecht University

Aletta Kraneveld studied Pharmacy at the schools of Pharmacy at University of Amsterdam and Utrecht University. As a junior researcher she worked at the department of Gastrointestinal Pharmacology of Glaxo Group Research in the UK (1990-1991). She obtained her PhD at the department of Pharmacology, Faculty of Pharmacy, Utrecht University (1994) after which she did an internship at the department of Pathology, Harvard Medical School Boston MA, USA (PI Steve Galli). As a post doc she continued her research as immune-pharmacologist in Utrecht.


Alexis Mosca

Physician Pediatrics
Robert-Debré Hospital

John Kokai-Kun

VP, Non-Clinical Affairs
Synthetic Biologics

Katri Korpela

Department of Bacteriology and Immunology, University of Helsinki

Dr Maria Kyrgiou

Clinical Senior Lecturer
Imperial College London

Dr Maria Kyrgiou is a Clinical Senior Lecturer at Imperial College London and Consultant Gynaecologist and Gynaecologic Oncologist at the West London Gynaecological Cancer Centre, Imperial Healthcare NHS Trust.


Tine Rask Licht

Professor, Head of Research Group
National Food Institute, Technical University of Denmark

Tine Rask Licht heads the The National Food Institute research group on Intestinal Microbial Ecology. 

The focus of our research is on effects of diet on composition, activity and genetic exchange in the gut microbiota, as well as on effects of the gut environment on resistance to pathogenic infections. Additionally, we adress the impact of gut microbes on maturation and maintenance of the host immune system. We look at effects of whole food items as well as of prebiotic carbohydrates and probiotic bacteria.


Tim Luker

Director External Innovation, Global External R&D
Eli Lilly and Company

Thomas Clavel

Senior scientist
Technische Universität München

The main focus of our research is the study of intestinal microbiomes (the communities of microorganisms, their genomes, and surrounding environmental factors in the gut). Because intestinal microorganisms have a major impact on the physiology of their host, it is important to investigate and understand their diversity and functions. We focus primarily on the human, pig, and mouse gut microbiomes because of their relevance for health-related issues.


Sophie Leclercq

Post-doctoral researcher
Université catholique de Louvain

Sara Romano-Bertrand

Assistant Professor
Université Montpellier

I work on opportunistic bacterial pathogens from endogenous (from human-associated microbiota) or exogenous (environment) origins, involved in healthcare-associated infections (HAI). Conversely to true bacterial pathogens that accord with the Koch’s postulate, the study of opportunistic infections including HAI, require us to consider both opportunistic pathogens responsible for the infection, its natural reservoir an the microbial-associated communities.


Rose Szabady

Senior Staff Scientist
Vedanta Biosciences, Inc.

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Dr. Mike Romanos, Ph.D. serves as the Chief Executive Officer at Microbiotica Ltd. He served as the Chief Executive and Executive Director of Crescendo Biologics Limited. Dr. Romanos is employed at Midven Limited. He is Venture Partner of Rainbow Seed Fund. He has more than 20 years' biotech and pharmaceutical industry experience, and within the last 10 years has held international executive positions in GlaxoSmithKline R&D before moving to take leadership of Crescendo Biologics.


Martha Clokie

Professor of Microbiology
University of Leicester

My research is focused on how bacteriophages (viruses) influence the biology of their bacterial hosts. I work on cyanobacteria and in medical pathogens as in both systems bacteriophages play key roles in controlling the evolution and population dynamics of their hosts. Important information on the bacteriophage biology can be gleamed from sequencing their genomes and I have sequenced full and partial genomes of several bacteriophages.

2017 Sponsors

Media Partners

Become a Sponsor or Exhibitor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

The Agenda

What You Can Expect From This Year's Congress:

  • 250+ Academic and Industry Leaders Onsite
  • 40+ Thought Leaders on the Speaker Faculty
  • 50:50 Ratio of Academics-Industry
  • 19 One-on-One Private Meetings per Attendee

European Microbiome Congress agenda

Download Full Agenda


Millennium Mayfair Hotel, Grosvenor Square, London W1K 2HP

Kisaco Research is pleased to offer attendees of The European Microbiome Congress a discounted £195 (excl vat) rate including breakfast at the Millennium Mayfair Hotel during the duration of the event.

Telephone: 0044 (0) 207 629 9400 quote KISA261117 when booking.

Email: [email protected] quote KISA261117 when booking.

Cut off date for rooms is 29 October 2017.

Conference Packages

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering.

Academics, Clinicians, Students & Post-Doctoral Researchers
£795 +VAT
2-Day Main Conference
Daily Lunches & Refreshments
Post-Show Access to Presentations
Welcome Networking Reception
Poster Sessions
Complimentary Articles and Content
Pharmaceutical and Biotech
£1695 + VAT
2-Day Main Conference
Daily Lunches & Refreshments
Post-Show Access to Presentations
Welcome Networking Reception
Poster Sessions
Complimentary Articles and Content
Service Providers, Vendors
£1995 + VAT
2-Day Main Conference
Daily Lunches & Refreshments
Post-Show Access to Presentations
Welcome Networking Reception
Poster Sessions
Complimentary Articles and Content
Poster Session
Poster Session
Preparing registration...

Poster Presentation Submission

If you are looking to highlight your recent work to the wider microbiome community, the dedicated poster session is a great way to get your research noticed and further involve yourself with the congress. In order to present a poster, you need to be registered as a delegate. Poster space is assigned on a first come, first served basis. Your presentation will be displayed in a dedicated poster area, while presentation sessions will take place both in the breaks and alongside sessions at prescheduled times.


Rising Star Travel Grant

£200 Travel Grants are available for FIVE young researchers (defined as having completed their PhD within the last 5 years). To be considered for one of the Rising Star Travel Grants, you must submit an abstract before 31st October 2017.


Commercialisation Surgery

Attendees are invited to pose questions and seek advice from a panel of industry leaders who have been through the commercialisation process.


Innovation Stage

Academics and early stage start-ups are invited to present innovations that they are looking to commercialise. Whether you are looking for investment or just want an expert’s opinion on the next steps in your commercialisation journey, this platform will be valuable for you. This platform allows FOUR presenters to share as much or as little information around their innovation as they feel comfortable, and receive tips and advice from a panel of expert investors, consultants, pharmaceutical companies, lawyers and successful start-ups, as well as input from the audience.

Book a Team to Save More!

Industry Rates Only: Team discounts cannot be combined with any other discount or offer

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

Payment Terms for the the Microbiome Conference:

  • Please note that a £49 processing fee will apply to any invoices requested.
  • * You must email us a signed letter from the Hospital / Clinic Supervisor or University / Laboratory with confirmation of your status upon payment
  • All Prices are in GBP
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • All discount offers cannot be combined with any other offer.
  • Please view our Cancellation Policy.
  • All Price exclude GB VAT of 20% – GB201759917

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us


Download Resource